Distinguished in Anaphylaxis

Antoine Deschildre

CHU Lille
Lille, FR 
Distinguished in Anaphylaxis
CHU Lille
Lille, FR 
OverviewLocationsClinical Research

Overview

Antoine Deschildre practices in Lille, France. Mr. Deschildre is rated as a Distinguished expert by MediFind in the treatment of Anaphylaxis. His top areas of expertise are Asthma, Asthma in Children, Food Allergy, and Anaphylaxis.

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles in the study of Anaphylaxis.

Gender
Male

Locations

CHU Lille
Lille, 59037, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.
A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.
Enrollment Status: Completed
Publish Date: December 16, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

152 Total Publications

Guidelines from the SP2A (Pediatric Society of Pulmonology and Allergology) for the management of asthma in children aged 6 to 12years (without management of asthma exacerbation) - Short version
Guidelines from the SP2A (Pediatric Society of Pulmonology and Allergology) for the management of asthma in children aged 6 to 12years (without management of asthma exacerbation) - Short version
Journal: Revue des maladies respiratoires
Published: August 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Deschildre's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile